Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Downgrades Neoleukin Therapeutics to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.
byBenzinga Newsdesk
November 16, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Robert Burns downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts